Search bioRxiv⌕ Search

Biology subjects

Saber-Ayad, M.

Publications and source records attributed to Saber-Ayad, M..

3 recordsLinked to original sources

Decoding Breast Cancer Heterogeneity via Multi-Omics Integration and Language Model-Based Interpretation

We present a novel pipeline combining Multi-Omics Factor Analysis (MOFA) and fine-tuned Large Language Models (LLMs) to predict breast cancer subtypes using proteomics, DNA methylation, and RNA-Seq data. Breast cancer is a heterogeneous disease characterized by diverse molecular alterations across multiple biological layers, necessitating integrative approaches for accurate subtype classification. Our methodology leverages MOFA for dimensionality reduction to identify key latent factors driving het-erogeneity, followed by LLM fine-tuning on these multi-omics signatures to enhance prediction accuracy. MOFA analysis identified five key latent factors capturing distinct biological processes: immune response, cell cycle regulation, metabolic reprogramming, tumor microenvironment interactions, and DNA repair mechanisms. We extracted the top features per omics layer for each factor and performed Gene Set Enrichment Analysis (GSEA) to characterize their biological significance. Our LLM, trained on curated multi-omics signatures and clinical metadata encoded as structured text prompts, significantly outperformed conventional statistical models in subtype classification, achieving AUC=0.93 and accuracy=0.89, compared to Random Forest (AUC=0.87, accuracy=0.82) and SVM (AUC=0.85, accuracy=0.80). The superior performance of our approach is attributed to the LLMs ability to capture complex, non-linear relationships and hierarchical feature interactions across omics layers. This integrative pipeline provides both improved predictive performance and interpretable biological insights, offering potential for enhanced clinical decision-making in breast cancer management.

cancer biology↗

Nischarin negatively impacts ShcD-mediated tumor cell migration

ShcD was previously found to promote cell motility in melanoma cells. Screening of a yeast two hybrid mouse embryo cDNA library identified Nischarin, a negative regulator to cell motility, as an interacting partner to the ShcD-CH2 domain. Therefore, we aimed to investigate the interaction between Nischarin and ShcD in mammalian cells and to determine their functional impact on cell migration. The Nischarin/ShcD interaction was confirmed by transfection and co-immunoprecipitation assays using full-length constructs in HEK293, MCF7 and MM253 cell lines. Deletion of the first 93 amino acids of ShcD abrogated the interaction indicating the importance of these residues for Nischarin binding. Co-expression of Nischarin and ShcD demonstrated an inhibitory effect on the levels of phospho-ERK and phospho-LIMK. In support of this, Nischarin was found to block the migratory activities of ShcD. A brief in silico analysis of publicly available breast cancer patient data was performed to elucidate the effect of Nischarin/ShcD co-expression on the patients overall survival. Patients with high expression of both proteins had better survival than those with only ShcD overexpression. Our results reveal that the novel protein Nischarin is an interacting partner to ShcD. In addition, we report that the tumour suppressive abilities of Nischarin can overcome ShcD-mediated cell migration when both proteins are concomitantly expressed. *This abstract was presented in the National Cancer Research Institute (NCRI)-2019

molecular biology↗

COVIDier: A Deep-learning Tool For Coronaviruses Genome And Virulence Proteins Classification

COVID-19, caused by SARS-CoV-2 infection, has already reached pandemic proportions in a matter of a few weeks. At the time of writing this manuscript, the unprecedented public health crisis caused more than 2.5 million cases with a mortality range of 5-7%. The SARS-CoV-2, also called novel Coronavirus, is related to both SARS-CoV and bat SARS. Great efforts have been spent to control the pandemic that has become a significant burden on the health systems in a short time. Since the emergence of the crisis, a great number of researchers started to use the AI tools to identify drugs, diagnosing using CT scan images, scanning body temperature, and classifying the severity of the disease. The emergence of variants of the SARS-CoV-2 genome is a challenging problem with expected serious consequences on the management of the disease. Here, we introduce COVIDier, a deep learning-based software that is enabled to classify the different genomes of Alpha coronavirus, Beta coronavirus, MERS, SARS-CoV-1, SARS-CoV-2, and bronchitis-CoV. COVIDier was trained on 1925 genomes, belonging to the three families of SARS retrieved from NCBI Database to propose a new method to train deep learning model trained on genome data using Multi-layer Perceptron Classifier (MLPClassifier), a deep learning algorithm, that could blindly predict the virus family name from the genome of by predicting the statistically similar genome from training data to the given genome. COVIDier able to predict how close the emerging novel genomes of SARS to the known genomes with accuracy 99%. COVIDier can replace tools like BLAST that consume higher CPU and time.

bioinformatics↗